SCHEMBL1047072

SCHEMBL1047072

CNC(=O)c1ccc(Nc2nc(Nc3ccccc3S(N)(=O)=O)cc3cc[nH]c(=O)c23)cc1C

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 5/20 0.51
FER P16591 1/20 0.40
KMT2A Q03164 1/20 0.38
JAK2 O60674 7/20 0.38
KCNH2 Q12809 4/20 0.38
BCAT2 O15382 1/20 0.38
LYN P07948 1/20 0.38
SYK P43405 1/20 0.38
ULK1 O75385 1/20 0.37
PTK2 Q05397 2/20 0.37
JAK1 P23458 6/20 0.36
TYK2 P29597 6/20 0.36
PKMYT1 Q99640 1/20 0.35
KIT P10721 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1045805 0.83 ZAP70 (0.58) ZAP70FERJAK2KCNH2BCAT2
SCHEMBL1048163 0.81 ZAP70 (0.49) ZAP70FERKMT2AJAK2BCAT2
SCHEMBL1048250 0.80 ZAP70 (0.50) ZAP70FER
SCHEMBL1049110 0.79 ZAP70 (0.68) ZAP70FERJAK2KCNH2LYN
SCHEMBL13753029 0.78 ZAP70 (0.48) ZAP70FERJAK2KCNH2BCAT2
SCHEMBL1047853 0.76 ZAP70 (0.49) ZAP70FERJAK2KCNH2LYN
SCHEMBL1047822 0.76 ZAP70 (0.54) ZAP70FERJAK2KCNH2LYN
SCHEMBL1048284 0.75 ZAP70 (0.51) ZAP70FERJAK2KCNH2LYN
SCHEMBL1047387 0.75 ZAP70 (0.77) ZAP70KMT2AJAK2KCNH2LYN
SCHEMBL1048423 0.75 ZAP70 (0.47) ZAP70FERJAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP claimed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO claimed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP disclosed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET ZAP70 4/4885FER 7/4885KMT2A 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.